How Biotin Affects Your Blood Test Results

Biotin, a B vitamin found in hair, skin, and nail supplements, can significantly distort blood test results by interfering with the laboratory technology used to measure everything from thyroid hormones to cardiac markers. The interference pushes some test values falsely high and others falsely low, depending on the type of assay, and the consequences range from unnecessary follow-up testing to dangerously wrong diagnoses. The problem is well recognized among laboratory scientists but remains largely underappreciated by the clinicians ordering the tests and the patients taking the supplements.

Why Biotin Causes the Problem

Many modern blood tests rely on a molecular pairing between biotin and a protein called streptavidin. This pairing forms one of the strongest bonds found in nature, and lab manufacturers exploit that strength to build highly sensitive tests called immunoassays.¹ In a nutshell, the test kit uses biotin-labeled molecules to capture or detect the substance being measured. When everything works as designed, only the tiny amount of biotin built into the test kit is present, and it binds streptavidin exactly where the manufacturer intended.

The trouble starts when you have been swallowing extra biotin as a supplement. Biotin from pills enters your bloodstream, and some of it is still circulating when your blood is drawn. That free-floating biotin competes with the biotin engineered into the test kit for the same streptavidin binding sites.² The result is like adding extra puzzle pieces from the wrong box: the assay’s internal chemistry gets thrown off, and the final number the lab reports no longer reflects what is actually in your blood.

Which Direction the Numbers Shift

Not all tests go wrong in the same direction, and understanding the pattern matters. Blood tests that use the biotin-streptavidin system generally fall into two architectural categories, and the direction of the error depends on which category a given test belongs to.

In competitive immunoassays, the kind typically used to measure small molecules like thyroid hormones, vitamin D, and steroid hormones, excess biotin causes the reported value to read falsely high.³ In sandwich immunoassays, the format used for larger molecules like TSH, troponin, and parathyroid hormone, the opposite happens: excess biotin pushes the reported value falsely low.³ A comprehensive assessment of affected assays found that the most dramatic false decreases appeared in high-sensitivity troponin T, TSH, and follicle-stimulating hormone, while the most dramatic false increases showed up in triiodothyronine (T3) and vitamin D results.⁴

The practical danger here is that the two directions of error can create a convincing but completely fictional clinical picture. A person taking biotin might have blood work that simultaneously shows elevated free T4 and T3 (falsely high from competitive assays) alongside suppressed TSH (falsely low from a sandwich assay). That pattern looks exactly like hyperthyroidism on paper, even if the person’s thyroid is perfectly normal.

Thyroid Tests Are Especially Vulnerable

Thyroid function panels are the most commonly cited victims of biotin interference, and for good reason. The combination of falsely elevated free T4 and free T3 with falsely suppressed TSH mimics the hallmark laboratory pattern of Graves’ disease. Case reports describe patients taking 20 to 30 milligrams of biotin daily whose thyroid panels shifted so dramatically that clinicians initially pursued workups for hyperthyroidism.⁵ The patients were clinically well, with no symptoms of thyroid disease, but their lab results told a different story.

This problem has also surfaced in patients with multiple sclerosis taking high-dose biotin (100 to 300 mg daily) as an experimental therapy. Reports describe lab values suggestive of thyrotoxicosis that prompted unnecessary evaluations, all of which resolved once biotin was stopped and the test was repeated.⁶ The interference was later confirmed by retesting on platforms that do not use biotin-streptavidin chemistry, which returned normal results.⁷

Parathyroid Hormone, Vitamin D, and Kidney Disease

The interference extends well beyond thyroid panels. Parathyroid hormone (PTH) is measured using sandwich immunoassays on many platforms, so biotin drives it falsely low. In patients on hemodialysis, who already require careful monitoring of PTH and vitamin D to manage bone health, the consequences can be severe. One published case described a woman on dialysis taking just 10 mg of biotin daily whose PTH plummeted from over 900 to 63 pg/mL on paper, while her vitamin D appeared to spike from 25 to above 100 ng/mL.⁸ Both values returned to their true baseline after she stopped the supplement.

In that clinical context, a falsely low PTH could lead a physician to withhold treatment that the patient actually needs, or a falsely high vitamin D could trigger dose reductions in vitamin D therapy. The original case series on this topic noted that unbound biotin molecules in serum directly compete with the assay’s biotinylated components, producing falsely depressed PTH values through standard ELISA-based measurement.⁹ Kidney patients are a particularly at-risk group because many take biotin-containing supplements for skin symptoms associated with dialysis, creating a perfect collision between supplement use and frequent lab monitoring.

Cardiac Troponin and the Stakes of a Missed Heart Attack

High-sensitivity cardiac troponin T is one of the most biotin-sensitive assays in use. Even relatively low concentrations of circulating biotin can push troponin values down because the test uses a sandwich format.¹⁰ The clinical stakes here are about as high as they get. Troponin is the primary blood marker used to diagnose heart attacks. If biotin artificially suppresses that number, a patient experiencing a genuine cardiac event could have a troponin level that reads as “normal,” potentially delaying treatment.

Laboratory characterization work has shown that troponin T is among the assays most sensitive to interference at lower biotin concentrations, meaning you do not need to be taking massive supplement doses for the error to occur.¹⁰ This is one of the clearest safety risks associated with unreported biotin use.

Pregnancy Tests and Reproductive Hormones

Biotin interference also reaches into reproductive health testing. Human chorionic gonadotropin (hCG), the hormone measured by pregnancy tests, is affected when the assay relies on biotin-streptavidin binding. In a controlled study, urine samples that contained hCG plus a placebo produced positive results about 71% of the time on a biotin-dependent immunoassay, while samples containing hCG plus biotin produced positive results only 19% of the time.¹¹ In other words, biotin supplementation caused the test to miss a genuinely positive result roughly four times out of five.

When those same samples were re-tested on a platform that did not use biotin-streptavidin chemistry, the results came back as expected, confirming that the biotin was the culprit rather than any real change in hCG levels.¹¹ A false-negative pregnancy test can have real consequences for early prenatal care, medication decisions, and family planning.

Point-of-Care and Rapid Tests

The problem is not limited to large laboratory analyzers. Some point-of-care rapid tests also use biotin-streptavidin chemistry. An evaluation of seven rapid urine hCG test devices found that one device showed a marked decrease in control-line intensity at biotin concentrations above 5 μg/mL, which could produce invalid results and delay care.¹² Most of the devices tested were unaffected, so the vulnerability varies by manufacturer and design.

More concerning is the finding that a point-of-care HIV antigen-antibody combo assay can also be affected. Researchers spiked biotin into samples containing HIV-1 antigen and found that the antigen was no longer detected when biotin reached 200 ng/mL, a concentration achievable with supplement use.¹³ A false-negative HIV screening test carries obvious public health implications. These findings reinforce that the interference issue extends beyond the traditional hospital lab setting.

How Common the Problem Actually Is

Biotin supplements are not a niche product. A survey of outpatients found that about 7.7% reported taking biotin, and a separate analysis of emergency department plasma samples found that roughly the same proportion, about 7.4%, had biotin concentrations at or above the lowest known threshold for interference in commonly used immunoassays.¹⁴ That means roughly one in thirteen blood samples drawn in a clinical setting could have enough biotin on board to affect test results on vulnerable platforms.

The doses in over-the-counter hair, skin, and nail supplements typically range from about 2.5 to 10 mg, which is already hundreds to thousands of times the adequate daily intake of 30 micrograms for adults. The fact that interference has been documented at the lower end of supplement dosing makes this more than a theoretical concern for people taking high therapeutic doses. The rising popularity of beauty-marketed biotin products means more routine blood draws are potentially affected than ever before.

Not Every Test Is Affected

An important point that often gets lost in the alarm: not all lab tests use biotin-streptavidin chemistry, and not all platforms from the same manufacturer are equally susceptible. Tests built on different binding systems, such as those using alternative linking molecules, are immune to biotin interference. When clinicians suspect interference, one straightforward step is retesting the sample on an alternative platform that does not use the biotin-streptavidin system.¹⁵

Even among tests that do use the system, sensitivity varies widely. Some assays, like troponin T, TSH, and antithyroid antibodies, react to relatively low concentrations of biotin, while the majority are more resistant and only show significant interference at much higher levels.¹⁰ At very high concentrations, though, essentially all assays in the biotin-streptavidin family show measurable error.

What Laboratories Can Do

Labs have developed several strategies to catch and correct biotin interference. Proposed best-practice workflows include serial dilution of the sample, retesting after biotin clearance or on a different platform, and direct measurement of the biotin concentration in the sample itself.¹⁵ One validated technique uses streptavidin-coated magnetic particles to physically strip excess biotin out of the sample before running the assay. This approach has been shown to remove biotin interference even from samples collected from multiple sclerosis patients receiving 300 mg of biotin daily, restoring results to normal values across both competitive and sandwich assay formats.¹⁶

These lab-side fixes work but require the laboratory to first suspect that biotin might be present. In routine practice, that suspicion often arises only after a clinician calls to say the results do not match the patient’s clinical picture, which brings the conversation back to awareness.

The Awareness Gap

Perhaps the most frustrating aspect of biotin interference is that it is well documented in laboratory medicine literature but remains largely unrecognized by the clinicians ordering the tests. A review of the issue described it bluntly: although the potential for biotin interference is well known to laboratory professionals, it remains largely unrecognized by clinicians, leading to misdiagnosis and inappropriate patient management.¹⁷ The FDA issued a safety communication in 2017 warning about the risk, prompted in part by at least one reported death linked to a falsely low troponin result in a patient taking biotin. Case reports following the FDA warning continued to appear, underscoring the ongoing nature of the problem.¹⁸

The gap is partly structural. Supplement intake is not routinely collected during pre-test questionnaires the way prescription medications are. Many patients do not think of biotin as something worth mentioning to their doctor because it is sold over the counter and marketed as a beauty product, not a drug. And many clinicians do not ask about over-the-counter supplements before ordering lab work.

What You Should Do Before a Blood Draw

If you take biotin supplements of any dose, the simplest step is to stop taking them before scheduled blood work. The specific recommended window depends on how much you are taking. For standard supplement doses in the range of 5 to 10 mg per day, stopping for at least two days before a blood draw is generally considered sufficient, because biotin clears from the bloodstream fairly quickly, with a terminal half-life in the range of roughly a day. For patients on high therapeutic doses of 100 mg or more, longer washout periods of up to a week are sometimes recommended to get blood levels below the interference threshold.

Animal pharmacokinetic data suggests that biotin clearance is faster than older estimates assumed, occurring in multiple phases with a final phase half-life around 22 hours.¹⁹ Human clearance times track somewhat differently, but the general principle holds: stop taking the supplement well in advance, and most of it will be gone by the time blood is drawn. If you are in a situation where blood work is done without warning, such as an emergency room visit, mention your biotin use to the treating team so the lab can account for it.

Not All Biotin Comes From a Standalone Supplement

A common blind spot is that biotin appears in products you might not associate with the vitamin. Multivitamins, prenatal vitamins, B-complex formulations, and specialty supplements marketed for energy or metabolism often include biotin. The amounts in multivitamins tend to be low (30 to 100 micrograms), which is unlikely to cause meaningful interference. But some B-complex products contain 1 to 5 mg, which edges into the range where sensitive assays can be affected. If you are trying to clear biotin before lab work, check the label of every supplement you take, not just the bottle that says “biotin” on the front.

Prescription-level biotin exposure is another consideration. Patients with certain rare metabolic conditions, such as biotinidase deficiency, take therapeutic biotin, and the multiple sclerosis context involves doses of 100 to 300 mg daily. These populations face the highest interference risk, but they also tend to be under closer medical supervision. The larger public health concern is the millions of people casually taking 5 to 10 mg beauty supplements without telling their doctors, because those individuals are less likely to be flagged in the clinical workflow.

How Manufacturers Are Responding

Some assay manufacturers have begun redesigning their platforms to reduce or eliminate biotin susceptibility. Newer versions of certain immunoassay reagents incorporate higher concentrations of streptavidin or use alternative binding strategies that are less vulnerable to competition from circulating biotin. However, the installed base of older analyzers and reagent kits is enormous, and laboratories do not replace their equipment overnight. The transition is happening, but it will be years before biotin-susceptible assays disappear from routine clinical use.

In the meantime, some labs have added alerts to their electronic ordering systems that prompt clinicians to ask about biotin use when ordering susceptible tests. Others have begun including disclaimers on result printouts noting that biotin supplements can affect specific analytes. These are useful but imperfect solutions, since they depend on someone actually reading the alert and acting on it.